Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

Of those, over 215,000 had been prescribed a glucagon-like peptide-1 (GLP-1) agonist receptor — the class of drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound, and others — and 1.7 ...

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

This hormone slows the rate of how the stomach is emptied and regulates blood sugar. Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, ...

The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its ... can result in a steep correction. Lilly is by no means in bad shape, but because the stock's price ...

Novo is under pressure to boost its development credentials in its rivalry with Zepbound-maker Eli Lilly after a late-stage trial read-out on another next-generation obesity drug known as ...

And everyone in the study had diabetes, so no one was taking these medications ... Wegovy, Mounjaro and Zepbound, may change a person's overall health. The study, published Monday in the journal ...

One reason is pressure from American drugmaker Eli Lilly, which makes competing products Zepbound and Mounjaro (alternatives to Wegovy and Ozempic, respectively). Novo’s stock fell slightly in ...